Leptin promotes endothelial dysfunction in chronic kidney disease through AKT/GSK3β and β-catenin signals

Biochemical and Biophysical Research Communications

Volumn 480, Issue 4, 2016, Pages 544-551

  Ding, Nannan ^a   Liu, Bing ^a   Song, Jiaguang ^a   Bao, Shougang ^b   Zhen, Junhui ^c   Lv, Zhimei ^a   Wang, Rong ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

AKT pathway; Chronic kidney disease; Endothelial dysfunction; F actin remodeling; Leptin

Indexed keywords

BETA CATENIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; F ACTIN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; PROTEIN KINASE B; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VINCULIN; CTNNB1 PROTEIN, HUMAN;

ADULT; ANTHROPOMETRY; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL MOTILITY; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIET RESTRICTION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOCAL ADHESION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; BLOOD; CHRONIC KIDNEY FAILURE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

BETA CATENIN; ENDOTHELIUM, VASCULAR; FEMALE; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; LEPTIN; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; VASCULAR RESISTANCE;

EID: 84994512369     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.10.079     Document Type: Article

References (21)

1. [1] Sivakumar Ardhanari, M.A.A., Aggarwal, Kul, Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention. Adv. Perit. Dial., 30, 2014.
2. [2] Ibrahim, H.S., Omar, E., Froemming, G.R.A., Singh, H.J., Leptin increases blood pressure and markers of endothelial activation during pregnancy in rats. Biomed. Res. Int. 2013 (2013), 1–6.
3. [3] Hou, N.L.J., Leptin and cardiovascular diseases. Clin. Exp. Pharmacol. Physiol. 38 (2011), 905–913.
4. [4] Anoop Shankar, S.S., Xiao, Jie, Muntner, Paul, Relationship between plasma leptin level and chronic kidney disease. Int. J. Nephrol., 2012, 2012.
5. [5] Stephan Goetze, F.E., Bungenstock, Anne, et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem. Biophs. Res. Commun. 293 (2002), 1431–1437.
6. [6] Beckers, Cora M.L., G-V, J.J., van Hinsbergh, Victor W.M., van Nieuw Amerongen, Geerten P., Nuclear targeting of β-catenin and p120ctn during thrombin-induced endothelial barrier dysfunction. Cardiovasc. Res. 79 (2008), 679–688.
7. [7] Foundation, N.K., K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39 (2002), S1–S266.
8. [8] Celermajer, D.S.S.K., Gooch, V.M., Spiegelhalter, D.J., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (1992), 1111–1115.
9. [9] Tedgui, A., Mallat, Z., Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86 (2006), 515–581.
10. [10] Wallace, A.M., MA, Packard, C.J., Kelly, A., et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland coronary prevention study (WOSCOPS). Circulation 104 (2001), 3052–3056.
11. [11] Vandana Menon, X.W., Greene, Tom, Beck, Gerald J., et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am. J. Kidney Dis. 42 (2003), 44–52.
12. [12] Deanfield, J.E., Halcox, J.P., Rabelink, T.J., Endothelial function and dysfunction: testing and clinical relevance. Circulation 115 (2007), 1285–1295.
13. [13] Matsuzawa, Y., Kwon, T.G., Lennon, R.J., et al. Prognostic value of flow-mediated vasodilation in brachial artery and fingertip artery for cardiovascular events: a systematic review and meta-analysis. J. Am. Heart Assoc., 4, 2015, e002270.
14. [14] Endemann, D.H., ELS, Endothelial dysfunction. J. Am. Soc. Nephrol. 15 (2004), 1983–1992.
15. [15] Mykhaylo Korda, R.K., Patton, Stephen, et al. Leptin-induced endothelial dysfunction in obesity. Am. J. Physiol. Heart Circ. Physiol. 295 (2008), 1514–1521.
16. [16] Yuan, D., He, P., Vascular remodeling alters adhesion protein and cytoskeleton reactions to inflammatory stimuli resulting in enhanced permeability increases in rat venules. J. Appl. Physiol. 113 (2012), 1110–1120.
17. [17] Rousseau, S., Houle, F., Kotanides, H., et al. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J. Biol. Chem. 275 (2000), 10661–10672.
18. [18] Karry, M., Jannie, S.M.E., Zhou, Dennis W., Chen, Sophia, et al. Vinculin-dependent actin bundling regulates cell migration and traction forces. Biochem. J. 465 (2015), 383–393.
19. [19] Xue, G., Hemmings, B.A., PKB/Akt–dependent regulation of cell motility. J. Natl. Cancer Inst., 2013, djs648.
20. [20] Ho, Y.-P., Kuo, C.-W., Hsu, Y.-T., et al. β-Actin is a downstream effector of the PI3K/AKT signaling pathway in myeloma cells. Mol. Cell Biochem 348 (2011), 129–139.
21. [21] Skurk, C., Maatz, H., Rocnik, E., et al. Glycogen-synthase kinase3β/β-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Circ. Res. 96 (2005), 308–318.